| RESEARCH ARTICLE |
|
| Year : 2007 | Volume
: 39
| Issue : 6 | Page : 299-302 |
Serum glucose and triglyceride lowering activity of some novel glitazones against dexamethasone-induced hyperlipidemia and insulin resistance
BR Prashantha Kumar1, TK Praveen1, MJ Nanjan1, MD Karvekar2, B Suresh1
1 TIFAC CORE JSS College of Pharmacy, Rocklands, Ootacamund - 643 001, Tamil Nadu, India
2 Government College of Pharmacy, P Kalingarao Road, Bangalore - 560 027, Karnataka, India
Correspondence Address:
M J Nanjan
TIFAC CORE JSS College of Pharmacy, Rocklands, Ootacamund - 643 001, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.39151
Objectives: To study the serum glucose and triglyceride lowering activity of some novel glitazones against dexamethasone-induced hyperlipidemia and insulin resistance in rats.
Materials and Methods: Serum glucose and triglyceride lowering activity of the test compounds and a standard, rosiglitazone, was tested at a dose of 10 mg/kg p.o. against dexamethasone-induced hyperlipidemia and insulin resistance in Sprague-Dawley (SD) rats. On day 11 of treatment, blood was collected for the estimation of serum glucose and triglyceride levels.
Results: All the 14 compounds and rosiglitazone significantly ( P < 0.05) decreased dexamethasone-induced elevation of serum glucose when compared to dexamethasone-alone-treated group. Among these compounds, compound 10 showed better antihyperglycemic activity than rosiglitazone. Compounds 7, 8 and 9 have shown significant ( P < 0.05) serum triglyceride lowering activity than did rosiglitazone. Out of the 14 compounds tested, only compounds 7, 8 and 9 have shown both serum glucose and triglyceride lowering activity.
Conclusion: The present study indicates that some of the newer glitazones show significant glucose and triglyceride lowering activity. In comparison to rosiglitazone, these glitazones show comparable serum glucose lowering and better triglyceride lowering activity.
[FULL TEXT] [PDF]*
|
